TRACK(S): ONC

Moderator: Howard L. Kaufman, MD, FACS, Boston, MA
Co-Moderator: Kenneth K. Tanabe, MD, FACS, Boston, MA

This Panel Session will provide an update on recent Food and Drug Administration (FDA) approval of Programmed Death Receptor 1 Ligand (PD L1)-directed immunotherapy in Merkel cell carcinoma, and it will describe the implications of this advance for other solid tumors associated with viral etiologies.

Presentations and Speakers

Lessons from Checkpoint Inhibitor Treatment of Merkel Cell Carcinoma 
Howard L. Kaufman, MD, FACS, Boston, MA

Advances in Immunotherapy of Anal Cancer
Cathy Eng, MD, Houston, TX

The Shifting Role of Surgical Management in the Era of Immuno-Oncology
Kenneth K. Tanabe, MD, FACS, Boston, MA